Generating 3D Molecular Structures Conditional on a Receptor Binding Site with Deep Generative Models

Tomohide Masuda∗
Comp. & Systems Biology
University of Pittsburgh
Pittsburgh, PA 15213
tmasuda@pitt.edu

Matthew Ragoza∗
Comp. & Systems Biology
University of Pittsburgh
Pittsburgh, PA 15213
mtr22@pitt.edu

David Ryan Koes
Comp. & Systems Biology
University of Pittsburgh
Pittsburgh, PA 15213
dkoes@pitt.edu

Abstract

Deep generative models have been applied with increasing success to the generation of two dimensional molecules as SMILES strings and molecular graphs. In this work we describe for the first time a deep generative model that can generate 3D molecular structures conditioned on a three-dimensional (3D) binding pocket. Using convolutional neural networks, we encode atomic density grids into separate receptor and ligand latent spaces. The ligand latent space is variational to support sampling of new molecules. A decoder network generates atomic densities of novel ligands conditioned on the receptor. Discrete atoms are then ‘fit’ to these continuous densities to create molecular structures. We show that valid and unique molecules can be readily sampled from the variational latent space defined by a reference ‘seed’ structure and generated structures have reasonable interactions with the binding site. As structures are sampled farther in latent space from the seed structure, the novelty of the generated structures increases, but the predicted binding affinity decreases. Overall, we demonstrate the feasibility of conditional 3D molecular structure generation and provide a starting point for methods that also explicitly optimize for desired molecular properties, such as high binding affinity.

1 Introduction

The principal goal of drug discovery and design is to find novel molecules that bind to and alter the activity of target proteins. This entails a long and costly pipeline in which a massive chemical space is repeatedly filtered down into the subset of compounds most likely to be active. Computational methods promise to enhance this process through rapid scoring and ranking of large libraries of molecules prior to hit confirmation with experimental assays [1]. This approach, called virtual screening, is now a well-established component of the modern drug development toolkit.

Despite its successful applications [2, 3], virtual screening has inherent limitations. A complete exploration of chemical space is computationally intractable, and virtual screening does not propose compounds missing from existing libraries. Furthermore, it does not propose changes or alternatives to input compounds to improve their desired properties (lead optimization).

Generative models have the potential to overcome these limitations. Generative models try to learn the underlying distribution of chemical space and acquire the ability to sample this distribution to yield novel active compounds. Two of the most popular generative modeling methods are generative adversarial networks (GANs) [4] and variational autoencoders (VAEs) [5].

Efforts thus far to develop generative models for computational drug design have mainly involved learning to map from two-dimensional molecules to a continuous latent space, then exploring that

∗These authors contributed equally to this work

Preprint. Under review.
latent space to produce new molecules with desired properties. In this work, we describe for the first time a deep learning model that can represent and generate three-dimensional molecular structures conditional on the target 3D binding pocket. Using atomic density grids as input, we encode a 3D bound molecular structure, including the target binding pocket, to a latent space and decode it. We then apply a novel optimization algorithm to solve the inverse problem of fitting a 3D molecular structure to a generated atomic density grid and reliably produce valid molecules. We evaluate generated structures in terms of molecular validity, uniqueness and predicted binding affinity, as computed by a densely connected neural network implemented in gnina (https://github.com/gnina) 6.

1.1 Related Work

Given the advances made in computer vision over the past decade [7, 8], there has been a surge of interest in applying deep learning to drug discovery [9]. A close analogy to images for the 3D molecular structures is a grid of atomic densities, and this approach has been used successfully for binding discrimination for virtual screening [10, 11, 12], pose ranking for docking [10, 6], and binding affinity prediction [13, 6, 14, 15].

In deep learning methods for generative modeling, generative adversarial networks (GANs) and latent variable models such as variational autoencoders (VAEs) are widely used. Generative adversarial networks (GANs) [4] are complementary to latent variable models [16] and concurrently train a discriminative network to tell apart real and fake data, and a generative network to create samples that the discriminator classifies as real. Methods have been developed for generating image-like data from GANs [17] and for stabilizing their training dynamics [18, 19]. In VAEs, an encoder and decoder network are trained to map between the input space and a set of latent random variables that follow a predetermined distribution allowing the model to sample from the prior and create novel data samples.

In the domain of deep generative models for molecular generation, recurrent neural networks (RNN), which have been effective at modeling natural language, play a central role. To apply RNNs, the SMILES string format [20] is used as the molecular representation [21, 22]. However, RNNs based on SMILES have suffered from generating invalid SMILES strings that do not correspond to any molecules. Improvements have been made with grammar-based methods that ensure the correct context-free grammar of the output [23, 24, 25]. Additionally, similar molecules can have very different strings due to lack of permutation invariance, and randomization of SMILES traversal order was proposed to improve the quality of generated molecules [26]. VAEs in conjunction with SMILES were adopted to generate novel molecules from a trained continuous latent space [27, 28]. Conditional VAEs, which can sample novel outputs conditioned on some relevant information, were also proposed for generating SMILES strings. These have been successfully applied to generating molecules that have desired molecular properties or related gene expressions [28, 29].

Moreover, VAEs together with molecular graph representations [30, 31], which more naturally capture the invariances present in chemical structures, were proposed and can generate novel molecules step by step as molecular graph. Recently, VAEs which take molecular graph representations and generates
SELFIES [32] was also proposed [33]. GANs have also been applied to molecular generative models and used with reinforcement learning to successfully generate novel molecules with desired properties [34, 35].

Despite progress in generative modeling of molecules, strings and graphs are primarily two-dimensional approaches whereas atomic density grids [10] allow learning from 3D conformations. Though grids are not rotation invariant, they are permutation invariant and have no discontinuities. Grids also have a fixed size, while SMILES strings and molecular graphs scale with the number of atoms and bonds. Atomic densities are continuous, differentiable, and highly GPU parallelizable as well [36]. Because they are continuous, density grids must be converted into a discrete representation to generate molecules. Previous efforts overcame this challenge by using a recurrent captioning network to output SMILES strings for each density grid [37]. However, this conversion relinquishes the three-dimensional nature of the generative model. To address this problem of generating 3D molecular structures, we introduce novel atom fitting and bond adding algorithms that can convert continuous grids to discrete molecular structures [38]. In this work we describe for the first time a deep generative model that can generate 3D molecular structures conditioned on a three-dimensional (3D) binding pocket using conditional VAEs [39] in conjunction with GANs.

2 Methods

2.1 Molecular grid representation

We represent molecules in a grid format amenable to convolutional network training. To convert molecules to this format, we assign each atom a type based on a typing scheme that includes the element, aromaticity, hydrophobicity, and H-bond donor/acceptor state. Atoms are represented as continuous, Gaussian-like densities on a three-dimensional grid with separate channels for each atom type, analogous to an RGB image. Grids are centered on the molecule centroid and span a cube of side length 23.5Å with 0.5Å resolution, resulting in grid dimensions $N_x = N_y = N_z = 48$. To compensate for the lack of rotation invariance, molecules are randomly rotated during training. This is facilitated by computing grids on-the-fly using libmolgrid, an open-source, GPU-accelerated molecular gridding library [36].

2.2 Fitting molecules to generated grids

While it is straightforward to compute the grid representation of a molecule, the inverse problem of converting a density grid into a discrete molecular structure does not have an analytic solution. Instead, we approach it as an optimization problem that we solve using an iterative algorithm that combines beam search and gradient descent (see [38] for more details) in order to identify a set of atoms the best fit a given atomic density grid.

The atom fitting algorithm returns a set of atom types and coordinates. To create a valid molecule, we then assign bond based on distances between atoms, valence constraints, and atom type constraints. Since generated densities are often not ideal, we allow bond lengths as long as 4Å if needed to generate a single molecule. Inaccuracies in the generated geometry are resolved through energy minimization as described below.

2.3 Generative model architecture and training

We trained our deep generative models as conditional variational autoencoders (VAEs) [39] in conjunction with a GAN loss using the atomic density grid format as their input and output. Generator networks were trained as deep convolutional VAEs that took both a ligand and receptor density grid as input and produced a ligand density grid as output. The generator was trained to minimize the squared error, or L2 loss, of the output ligand density with respect to the input ligand density. An adversarial discriminative network was used to encourage the generated densities to match real densities from a more abstract perspective. The receptor binding site and ligand were encoded to distinct latent spaces by separate encoder branches, as seen in Figure 1. The ligand latent space was variational, such that its latent vectors were sampled from a normal distribution that was parameterized by the ligand encoder (posterior). The ligand latent space was also constrained to follow a standard normal distribution overall by a KL divergence loss function (prior). The receptor latent space was deterministic and was used to condition the learned prior and posterior distributions. The encoded
The encoder networks consisted of series of four convolution blocks with three convolution layers each having 32, 64, 128, or 256 filters. The encoder convolution blocks were interleaved with average pooling layers. The decoder network followed the same pattern in reverse, but interleaved its convolution blocks with nearest-neighbor upsampling instead. In two locations, convolutional outputs from the receptor encoder were concatenated with those of the ligand decoder in order to better propagate the 3D structural information of the receptor binding pocket at different resolutions while decoding the ligand.

The discriminator network had three convolution layers with filter sizes 16, 32, and 64, each followed by a leaky ReLU activation layer and an average pooling layer. The same kernel size of 3 was used in each of these convolution layers. The KL divergence, L2, and adversarial loss functions were combined with equal weight. Models were trained using the Adam optimization algorithm [40] with hyperparameters $\alpha = 1e^{-5}, \beta_1 = 0.9, \beta_2 = 0.999$ and a fixed learning rate policy for 100,000 iterations, using a batch size of 10.

2.4 Data sets

In order to train deep neural networks to generate molecules in 3D, we utilized the CrossDocked2020 data set [6]. This set includes training and test splits that cluster similar protein targets together to avoid overlap between training and test sets. It also attempts to mimic the drug discovery process by including ligand poses cross-docked against non-cognate receptor structure. Because our goal is to generate high-quality structures, we selected only low RMSD (< 2Å) poses, yielding a total of 725,048 poses. We use a single training/test split. We note that although training data for 3D molecular structure generation is fundamentally limited to what is available in the Protein Data Bank (https://www.rcsb.org), the use of cross-docked structures provides a reasonable means of data augmentation, expanding the number of training structures by an order of magnitude.

2.5 Evaluation procedure

We evaluated structures generated by our trained models by providing an input seed molecule and receptor to the network and performing atom fitting and bond adding on the generated grids. First, we evaluated generated molecules in terms of their validity and uniqueness. A generated molecule is considered valid if does not contain disconnected fragments and RDKit is able to sanitize the molecule. Uniqueness was determined by equality comparison of canonical SMILES string representations of the valid molecules. We also examined the molecular similarity of generated molecules to the seed molecule using the MACCS fingerprint with the Tanimoto coefficient.

Because generated molecules often had non-physical bond lengths and angles, we performed energy minimization for generated structure in the context of the fixed receptor using the UFF force field as implemented by RDKit. The optimized molecule was then further optimized with respect to the receptor using the Vina scoring function as implemented by gnina. Finally, we assessed the predicted binding affinity of optimized structures to the receptor using an ensemble of the densely connected CNN (Dense) models of gnina trained on CrossDocked2020 with five different seeds [6].

Figure 2: Ability to generate valid and unique molecules from a seed molecule and receptor using ten complexes from the test set for different variability factors.

ligand and receptor latent vectors were concatenated and provided to the decoder, which produced a grid of ligand atomic density.
For comparison, the reference seed ligand is also energy minimized with Vina. Vina optimization is necessary because the Dense CNN models are calibrated to such poses and because crystal ligands are not at an local optimum of the docking score, so comparisons to un-optimized structures would be misleading. We report the root mean squared deviation (RMSD) between the initial generated structure and the final optimized structure. Larger RMSDs imply the generated molecule was geometrically or sterically problematic as the atoms had to be moved more to get to a local optimum.

We performed these generation and evaluation steps 1,000 times per each receptor-ligand complex evaluated. In each evaluation, different densities were generated due to the random sampling fo the variational ligand latent space. For this evaluation we sampled 10 receptor-ligand complexes from the test set (1fkg, 2rd6, 3h7w, 3p0p, 3vrj, 4cg9, 4oq3, 4ps7, 5e19 and 5mku). We also evaluate structure generation as we increase the variability factor for sampling the ligand latent space. This is a multiplier of the generated variance [37]. A variability factor of 1.0 corresponds to the standard sampling used during training. Larger factors are expected to sample structures farther from the seed ligand. We also evaluated prior (no lig) sampling where the ligand latent space is sampled as a standard normal distribution.

3 Results

3.1 Molecular validity, uniqueness and variability factor

As shown in Figure 2, we succeeded in producing valid molecules with an average rate of over 80% at variability factor 1.0. More than 90% of these molecules are chemically unique and, as the variability factor is increased, the percentage of unique molecules approaches 100%. This shows that even though the generated molecules are sampled conditioned on a seed molecule, they are not merely recapitulating the input.

3.2 RMSD of optimization

Figure 3 shows how significantly the energy minimization steps changed the molecules. RDKit minimization optimizes the pose as well as the internal bond lengths and angles in the context of the receptor binding site. Vina minimization only optimizes the pose orientation and internal rotatable bonds in the context of the receptor. As the variability factor is increased, generated molecules are more likely to be farther from the local minimum of the optimized molecule. The overall median RMSD change is 1.65, 1.77, 2.09, 2.53, and 3.27 for variability factors of 1.0, 1.5, 3.0, 5.0 and prior sampling respectively. An RMSD less than 2Å is typically considered an acceptable amount of deviation for a docked pose [6]. As the variability factor is increased, the generated structures deviate more from the seed molecule, resulting in higher RMSD, but since they are also conditioned on the receptor, the RMSD change remains reasonable.
Figure 4: The cumulative distributions of UFF energy of the generated, unoptimized molecule and
the Vina energy score of the optimized molecule for structures sampled from the prior (no lig) with
and without a receptor structure. Also shown (right) is the distribution of topological polar surface
area (TPSA) of the generated molecules.

Figure 3 also shows cumulative distribution of Vina scores of the optimized molecules. As the
variability factor is increased, fewer good scoring (more negative) molecules are generated. However,
in all cases the majority of molecules have a negative score, indicating that reasonable optimized
poses were identified, and, taking into consideration the RMSD results, these poses are not far, in
most cases, from the unoptimized generated molecule.

3.3 Molecular size, similarity, and affinity scores

Figure 5 shows the change in the distribution of molecular size, similarity relative to the input
molecule, and affinity scores as the variability factor is increased. In most targets, the sizes of
generated molecules were smaller than the seed molecule and larger variability factors made them
smaller. Nonetheless, for most targets at least some molecules were generated that were larger than
the seed. In all cases, sampling without a seed ligand results in the widest distribution of generated
molecule sizes.

The affinity scores (Vina and CNN Affinity) and similarity also show a systematic tendency to shift
away from the seed molecule as the variability factor is increased. Larger variability factors make
affinity scores lower smaller and similarity smaller (as expected). Every target had at least a few
structures with better predicted affinity than the seed molecule when generated with variability factor
1.0. However, only two complexes, 3h7w and 5e19, had more than 15% of their generated molecules
have better Vina affinities, and these targets had 47% and 60% of generated molecules have a better
CNN predicted affinity.

As expected, as the variability factor is increased the similarity to the seed molecule decreases and,
in fact, very few highly similar molecules are sampled. With variability factor 1.0, the percent of
molecules with greater than 0.7 Tanimoto similarity ranged from 1% to 22%, but as the variability
factor is increased, this percentage quickly goes to zero. Although generated ligands have low
chemical similarity to the seed ligand, as can be seen in Figure 9, they appear to have high shape
similarity.

3.4 Relationship between affinity score and similarity

As both predicted affinity and similarity decrease as the variability factor is increased, we investigate
the relationship between these two values in Figure 6. As expected, as the variability factor increases
there is less similarity. Although in some cases these values are correlated (e.g. 4oq3 exhibits
the highest Pearson correlation of 0.55 with a variability factor of 1.0), in many cases there is no
correlation, and correlation is not necessary for high affinity ligands to be generated (e.g. 5e19 has a
correlation of 0.04, but generates the best scoring ligands). This suggests that success at generating
high scoring structures is not solely due to generating chemically similar structures.
Figure 5: Distributions of molecular weight, similarity with the seed molecule, Vina energy score, and CNN affinity score for optimized generated molecules for different variability factors and complexes. Vertical lines show the corresponding value for the seed molecule.
3.5 Conditionality on receptor

We investigate the extent that the generated structures are dependent on the receptor structure in Figure 4 which shows the overall cumulative distribution of energy scores of generated structures before and after optimization (distributions broken out by individual complexes are shown in Figure 7). Structures were generated with and without a receptor structure when sampling from the prior (no seed ligand provided). As expected, structures generated without the receptor were much more likely to have a high (unfavorable) energy before optimization. However, our optimization protocol reduces this difference significantly, although structures generated without the receptor have a higher RMSD after optimization (Figure 8). In addition to having distinctly different receptor interaction property distributions, the molecules have different molecular properties, most significantly the topological
polar surface area, also shown in Figure 4. We observe that receptors with solvent inaccessible, hydrophobic binding sites (e.g. 3h7w and 5mku) produce molecules with a lower TPSA while solvent exposed sites (e.g. 1fkg and 4oq3) exhibit a higher TPSA. Accordingly, molecules generated with no receptor also have significantly higher TPSA values.

3.6 Example structures

High scoring generated structures for two targets sampled at each variability factor are displayed in Figure 9. These examples were chosen from structures that are valid, have an RMSD change during optimization of < 2Å, and have good Vina and CNN affinity scores. As the variability factor is increased, the generated molecule becomes visually distinct from the seed molecule. For 3vrj, the generated structures sampled with variability factors over 1.5 have a Tanimoto coefficient less than 0.5 relative to the seed molecule and don’t retain the scaffold. In particular, the aromatic ring disappears and at a variability of 5.0 the generated structure is an open chain. For 4ps7, the structures generated with variability factors 1.0 and 1.5 look similar to the seed molecule and interactions such as hydrogen bonds are kept. Although their Tanimoto coefficients are less than 0.8, the scaffold of the seed molecule[41] is retained. The pyridine substructure included in the seed molecule is replaced with a larger non-aromatic ring and modification of this heterocyclic structure contributes to the reduction of Tanimoto coefficient. In the case of variability factor 3.0, the generated molecule has a distorted structure around the scaffold of this seed molecule and this makes it difficult to retain hydrogen bonds with the receptor. In the case of the factor 5.0, the generated molecule is totally different from the seed molecule and its Tanimoto coefficient is around 0.2. As expected, sampling without a seed molecule results in structures that are completely different both in terms of their chemical structure and their binding mode. Overall, molecules generated using larger variability factors tend to have unconventional scaffolds, pointing to the need to explicitly train models to generate drug-like molecules.

4 Discussion

By training deep generative models on atom density grids and applying our atom fitting and bond adding algorithms, we have developed the first deep learning model for generating fully three-dimensional molecular structures within binding pockets. Our model utilizes conditional VAEs and GANs and is conditional on a three-dimensional binding site. Whereas some works on molecular generative models using conditional VAEs have been developed, and they can successfully generate molecules, they are conditional on properties of the ligand, not the receptor[28]. Because our model generates fully three-dimensional molecular structures, the structure of the binding site is taken into account. Unique to our approach, the importance of the receptor is emphasized in the network architecture through the propagation of receptor information at different spatial resolutions to the decoder. Our model was able to generate valid molecules at a rate greater than 80% on average and most of the valid molecules were unique. When the ligand space is sampled close to a reference seed compound, it is possible to generate novel structures with better predicted binding affinities...
Figure 9: Sampled binding poses for 3vrj and 4ps7 at different variability factors (rows). The seed molecule (blue) is shown with a generated pose (green) with its Tanimoto similarity coefficient.
and similar size to the seed compound. Although generated structures typically do not produce ideal molecular geometries, usually only minimal changes (< 2 Å RMSD) are required to obtain a proper geometry. As the variability of sampling is increased, larger changes in molecular structure are observed and fewer of these structures are close to locally optimal conformations.

Future work will seek to further regularize the ligand latent space to impose an drug-likeness bias as others have done [28]. We are also interested in exploring ways to generate structures with better predicted binding affinities, either through exploration of the ligand latent space or by training models that are explicitly conditioned on binding affinity or other molecular properties. Such approaches are likely necessary in order to enable the effective generation of structures from a receptor structure without a reference seed ligand. Nonetheless, this work demonstrates the feasibility of conditional 3D molecular structure generation and provides a starting point for future improvements.

Acknowledgements

This work is supported by R01GM108340 from the National Institute of General Medical Sciences, is supported in part by the University of Pittsburgh Center for Research Computing through the resources provided, and used the Extreme Science and Engineering Discovery Environment (XSEDE), which is supported by National Science Foundation grant number ACI-1548562 through the Bridges GPU-AI resource allocation TG-MCB190049.

References

[1] Markus H. J. Seifert, Kristina Wolf, and Daniel Vitt. Virtual high-throughput in silico screening. BIOSILICO, 1(4):143–149, Sep 2003.
[2] Tian Zhu, Shuyi Cao, Pin-Chih Su, Ram Patel, Darshan Shah, Heta B Chokshi, Richard Szukala, Michael E Johnson, and Kirk E Hevener. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis: miniperspective. Journal of medicinal chemistry, 56(17):6560–6572, 2013.
[3] Peter Ripphausen, Britta Nisius, Lisa Peltason, and Jurgen Bajorath. Quo vadis, virtual screening? a comprehensive survey of prospective applications. Journal of medicinal chemistry, 53(24):8461–8467, 2010.
[4] Ian Goodfellow, Jean Pouget-Abadie, Mehdi Mirza, Bing Xu, David Warde-Farley, Sherjil Ozair, Aaron Courville, and Yoshua Bengio. Generative adversarial networks. arXiv preprint arXiv:1406.2661, 2014.
[5] Diederik P Kingma and Max Welling. Auto-encoding variational bayes. arXiv preprint arXiv:1312.6114, 2013.
[6] Paul G Francoeur, Tomohide Masuda, Jocelyn Sunseri, Andrew Jia, Richard B Iovanisci, Ian Snyder, and David R Koes. Three-Dimensional Convolutional Neural Networks and a Cross-Docked Data Set for Structure-Based Drug Design. J. Chem. Inf. Model., 60(9):4200–4215, 2020.
[7] Alex Krizhevsky, Ilya Sutskever, and Geoffrey E Hinton. Imagenet classification with deep convolutional neural networks. In Advances in Neural Information Processing Systems, pages 1097–1105, 2012.
[8] Yann LeCun, Yoshua Bengio, and Geoffrey Hinton. Deep learning. Nature, 521(7553):436–444, 2015.
[9] Christof Angermueller, Tanel Pärnamaa, Leopold Parts, and Oliver Stegle. Deep learning for computational biology. Mol. Syst. Bio., 12(878), 2016.
[10] Matthew Ragoza, Joshua Hochuli, Elisa Idrobo, Jocelyn Sunseri, and David Ryan Koes. Protein-Ligand Scoring with Convolutional Neural Networks. J Chem Inf Model, 57(4):942–957, 2017.
[11] Fergus Imrie, Anthony R Bradley, Mihaela van der Schaar, and Charlotte M Deane. Protein family-specific models using deep neural networks and transfer learning improve virtual screening and highlight the need for more data. Journal of chemical information and modeling, 58(11):2319–2330, 2018.
[12] Izhak Wallach, Michael Dzamba, and Abraham Heijts. AtomNet: A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-Based Drug Discovery. arXiv preprint:1510.02855, 2015.
[13] José Jiménez, Miha Škalič, Gerard Martínez-Rosell, and Gianni De Fabritiis. KDEEP: Protein–Ligand Absolute Binding Affinity Prediction via 3D-Convolutional Neural Networks. Journal of Chemical Information and Modeling, 58(2):287–296, 2018. PMID: 29309725.
[14] Marta M Stepniawska-Dziubinska, Piotr Zielenkiewicz, and Pawel Siedlecki. Development and evaluation of a deep learning model for protein–ligand binding affinity prediction. Bioinformatics, 34(21):3666–3674, 2018.
[15] Hussein Hassan-Harrirou, Ce Zhang, and Thomas Lemmin. Rosenet: Improving binding affinity prediction by leveraging molecular mechanics energies with an ensemble of 3d convolutional neural networks. *Journal of Chemical Information and Modeling*, 2020.

[16] Anders Boesen Lindbo Larsen, Søren Kaee Sonderby, Hugo Larochelle, and Ole Winther. Autoencoding beyond pixels using a learned similarity metric. *arXiv preprint arXiv:1512.09300*, 2016.

[17] Soumith Chintala Alec Radford, Luke Metz. Unsupervised representation learning with deep convolutional generative adversarial networks. *arXiv preprint arXiv:1511.06434*, 2016.

[18] Ishaan Gulrajani, Faruk Ahmed, Martin Arjovsky, Vincent Dumoulin, and Aaron Courville. Improved Training of Wasserstein GANs. *arXiv preprint arXiv:1704.00028v3*, 2017.

[19] Martin Arjovsky, Soumith Chintala, and Léon Bottou. Wasserstein GAN. *arXiv preprint arXiv:1406.2661*, 2017.

[20] David Weininger. SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules. *Journal of Chemical Information and Computer Sciences*, 28(1):31–36, 1988.

[21] Marwin H.S. Segler, Thierry Kogej, Christian Tyrchan, and Mark P. Waller. Generating focussed molecule libraries for drug discovery with recurrent neural networks. *arXiv preprint arXiv:1701.01329*, 2017.

[22] Esben J Bjerrum and Richard Threlfall. Molecular generation with recurrent neural networks (rnns). *arXiv preprint arXiv:1705.04612*, 2017.

[23] Matt J. Kusner, Brooks Paige, and José Miguel Hernández-Lobato. Grammar variational autoencoder. In Doina Precup and Yee Whye Teh, editors, *Proceedings of the 34th International Conference on Machine Learning*, volume 70 of *Proceedings of Machine Learning Research*, pages 1945–1954, International Convention Centre, Sydney, Australia, 06–11 Aug 2017. PMLR.

[24] Mariya Popova, Alexandr Isayev, and Alexander Tropsha. Deep reinforcement learning for de novo drug design. *Sci. Adv.*, 4(7), 2018.

[25] Hanjun Dai, Yingtao Tian, Bo Dai, Steven Skiena, and Le Song. Syntax-directed variational autoencoder for structured data. *arXiv preprint arXiv:1802.08786*, 2018.

[26] Josep Arús-Pous, Simon Johansson, Pykhodko Oleksii, Esben J Bjerrum, Christian Tyrchan, Jean-Louis Reymond, Hongming Chen, and Ola Engkvist. Randomized smiles strings improve the quality of molecular generative models. *ChemRxiv.org:8639942*, 2019.

[27] Rafael Gómez-Bombarelli, David Duvenaud, José Miguel Hernández-Lobato, Jorge Aguilera-Iparraguirre, Timothy D. Hirzel, Ryan P. Adams, and Alán Aspuru-Guzik. Automatic chemical design using a data-driven continuous representation of molecules. *arXiv preprint arXiv:1610.02415v1*, 2016.

[28] Jaechang Lim, Seongok Ryu, Jin W Kim, and Woo Y Kim. Molecular generative model based on conditional variational autoencoder for de novo molecular design. *J. Cheminf.*, 10(31), 2018.

[29] O Méndez-Lucio, B Baillif, D Clevert, D Rouquié, and J Wichard. De novo generation of hit-like molecules from gene expression signatures using artificial intelligence. *Nat Commun*, 11(10), 2020.

[30] Martin Simonovsky and Nikos Komodakis. GraphVAE: Towards Generation of Small Graphs Using Variational Autoencoders. *arXiv preprint arXiv:1802.03480v1*, 2018.

[31] Wengong Jin, Regina Barzilay, and Tommi Jaakkola. Junction Tree Variational Autoencoder for Molecular Graph Generation. *arXiv preprint arXiv:1802.04364v4*, 2019.

[32] Mario Krenn, Florian Häse, AkshatKumar Nigam, Pascal Friederich, and Alán Aspuru-Guzik. Self-referencing embedded strings (selfies): A 100representation. *Mach. Learn.: Sci. Technol.*, 2020.

[33] Jacques Boitreaud, Vincent Mallet, Carlos Oliver, and Jerome Waldispühl. Optimal : Optimization of Binding Affinities in Chemical Space for Drug Discovery. *bioRxiv:2020.05.23.12201*, 2020.

[34] Gabriel Guimaraes, Benjamin Sanchez-Lengeling, Carlos Outeiral, Pedro LC Farias, and Alán Aspuru-Guzik. Objective-reinforced generative adversarial networks (organ) for sequence generation models. *arXiv preprint arXiv:1705.10843v1*, 2017.

[35] Benjamin Sanchez-Lengeling, Carlos Outeiral, Gabriel L Guimaraes, and Alán Aspuru-Guzik. Optimizing distributions over molecular space. an objective-reinforced generative adversarial network for inverse-design chemistry (organic). *ChemRxiv.org:5309668*, 2017.

[36] Jocelyn Sunseri and David R Koes. libmolgrid: Graphics Processing Unit Accelerated Molecular Gridding for Deep Learning Applications. *J. Chem. Inf. Model.*, 60(3):1079–1084, 2020.

[37] Miha Skalic, José Jiménez, Davide Sabbadini, and Gianni De Fabritiis. Shape-Based Generative Modeling for de Novo Drug Design. *Journal of Chemical Information and Modeling*, 59(3):1205–1214, 2019. PMID: 30762364.

[38] Matthew Ragoza, Tomohide Masuda, and David Ryan Koes. Learning a continuous representation of 3d molecular structures with deep generative models. *arXiv preprint:XXXX.XXXXX*, 2020.
[39] Diederik P Kingma, Danilo J Rezende, Shakir Mohamed, and Max Welling. Semi-supervised Learning with Deep Generative Models. arXiv preprint arXiv:1406.5298v2, 2014.

[40] Diederik P. Kingma and Jimmy Lei Ba. Adam: A method for stochastic optimization. In Proceedings of the 3rd International Conference Learning Representations, 2015.

[41] Philip N Collier, Gabriel Martinez-Botella, Mark Cornebise, Kevin M Cottrell, John D Doran, James P Griffith, Sudipta Mahajan, Francois Maltais, Cameron S Moody, Emilie Porter Huck, Tiansheng Wang, and Alex M Aronov. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase γ. J. Med. Chem., 58(1), 2015.